Literature DB >> 24529150

Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

William R Lagor1, David W Fields2, Robert C Bauer2, Alison Crawford3, Michael C Abt3, David Artis3, E John Wherry3, Daniel J Rader2.   

Abstract

Apolipoprotein F (ApoF) is a sialoglycoprotein that is a component of the HDL and LDL fractions of human serum. We sought to test the hypothesis that ApoF plays an important role in atherosclerosis in mice by modulating lipoprotein function. Atherosclerosis was assessed in male low density lipoprotein receptor knockout (Ldlr KO) and ApoF/Ldlr double knockout (DKO) mice fed a Western diet for 16 weeks. ApoF/Ldlr DKO mice showed a 39% reduction in lesional area by en face analysis of aortas (p < 0.05), despite no significant differences in plasma lipid parameters. ApoF KO mice had reduced expression of Interferon alpha (IFNα) responsive genes in liver and spleen, as well as impaired macrophage activation. Interferon alpha induced gene 27 like 2a (Ifi27l2a), Oligoadenylate synthetases 2 and 3 (Oas2 and Oas3) were significantly reduced in the ApoF KO mice relative to wild type controls. These effects were attributable to hypomorphic expression of Stat2 in the ApoF KO mice, a critical gene in the Type I IFN pathway that is situated just 425 base pairs downstream of ApoF. These studies implicate STAT2 as a potentially important player in atherosclerosis, and support the growing evidence that the Type I IFN pathway may contribute to this complex disease.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ApoF; Atherosclerosis; STAT2; Type I IFN

Mesh:

Substances:

Year:  2014        PMID: 24529150      PMCID: PMC3936605          DOI: 10.1016/j.atherosclerosis.2013.12.043

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  29 in total

1.  Immune response in Stat2 knockout mice.

Authors:  C Park; S Li; E Cha; C Schindler
Journal:  Immunity       Date:  2000-12       Impact factor: 31.745

2.  Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions.

Authors:  Pieter Goossens; Marion J J Gijbels; Alma Zernecke; Wouter Eijgelaar; Monique N Vergouwe; Ingeborg van der Made; Joris Vanderlocht; Linda Beckers; Wim A Buurman; Mat J A P Daemen; Ulrich Kalinke; Christian Weber; Esther Lutgens; Menno P J de Winther
Journal:  Cell Metab       Date:  2010-08-04       Impact factor: 27.287

Review 3.  Cytokine-mediated inflammation, tumorigenesis, and disease-associated JAK/STAT/SOCS signaling circuits in the CNS.

Authors:  Iain L Campbell
Journal:  Brain Res Brain Res Rev       Date:  2005-01-15

4.  STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor.

Authors:  Stuart T Perry; Michael D Buck; Steven M Lada; Christian Schindler; Sujan Shresta
Journal:  PLoS Pathog       Date:  2011-02-17       Impact factor: 6.823

5.  Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus.

Authors:  Deanna M Santer; Taku Yoshio; Seiji Minota; Thomas Möller; Keith B Elkon
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

Review 6.  Interferons, interferon-like cytokines, and their receptors.

Authors:  Sidney Pestka; Christopher D Krause; Mark R Walter
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

7.  A user's guide to the encyclopedia of DNA elements (ENCODE).

Authors: 
Journal:  PLoS Biol       Date:  2011-04-19       Impact factor: 8.029

8.  The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice.

Authors:  William R Lagor; David W Fields; Sumeet A Khetarpal; Arthi Kumaravel; Wen Lin; Nathaniel Weintraub; Kaijin Wu; Sarah F Hamm-Alvarez; Denise Drazul-Schrader; Margarita de la Llera-Moya; George H Rothblat; Daniel J Rader
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

9.  STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response.

Authors:  Lan-Sun Chen; Pei-Chi Wei; Taming Liu; Chung-Hsuan Kao; Li-Mei Pai; Chien-Kuo Lee
Journal:  J Biomed Sci       Date:  2009-02-19       Impact factor: 8.410

10.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  12 in total

Review 1.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

2.  Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Authors:  Kelsey E Jarrett; Ciaran Lee; Marco De Giorgi; Ayrea Hurley; Baiba K Gillard; Alexandria M Doerfler; Ang Li; Henry J Pownall; Gang Bao; William R Lagor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

3.  ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters.

Authors:  Richard E Morton; Yan Liu; Lahoucine Izem
Journal:  J Lipid Res       Date:  2019-09-11       Impact factor: 5.922

4.  Genetic architecture and adaptations of Nunavik Inuit.

Authors:  Sirui Zhou; Pingxing Xie; Amélie Quoibion; Amirthagowri Ambalavanan; Alexandre Dionne-Laporte; Dan Spiegelman; Cynthia V Bourassa; Lan Xiong; Patrick A Dion; Guy A Rouleau
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-22       Impact factor: 11.205

5.  Structure-function relationships of HDL in diabetes and coronary heart disease.

Authors:  Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein
Journal:  JCI Insight       Date:  2020-01-16

Review 6.  Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.

Authors:  Malgorzata Szelag; Anna Piaszyk-Borychowska; Martyna Plens-Galaska; Joanna Wesoly; Hans A R Bluyssen
Journal:  Oncotarget       Date:  2016-07-26

7.  Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.

Authors:  Kelsey E Jarrett; Ciaran M Lee; Yi-Hsien Yeh; Rachel H Hsu; Rajat Gupta; Min Zhang; Perla J Rodriguez; Chang Seok Lee; Baiba K Gillard; Karl-Dimiter Bissig; Henry J Pownall; James F Martin; Gang Bao; William R Lagor
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

8.  Differentiation between thyroid-associated orbitopathy and Graves' disease by iTRAQ-based quantitative proteomic analysis.

Authors:  Jianshu Kang; Yunqin Li; Zhijian Zhao; Hong Zhang
Journal:  FEBS Open Bio       Date:  2021-05-26       Impact factor: 2.693

9.  Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients.

Authors:  Hang Yin; Cheng-Gong Liao; Jian-Guo Huang; Yong-Qiang Wang; Zheng Li; Lu-Lu Fan; Men-Long Qian; Nao Wan; Ning Lu
Journal:  Oncotarget       Date:  2017-06-19

Review 10.  Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis.

Authors:  Qi Chen; Jianjun Lv; Wenwen Yang; Baoping Xu; Zheng Wang; Zihao Yu; Jiawei Wu; Yang Yang; Yuehu Han
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.